DNAnexus and Galatea Bio have partnered to enhance biomedical research and precision medicine, focused on improving data services for Latin American populations as well as other under-represented groups.

As part of the agreement, Galatea Bio will employ DNAnexus' cloud-based data services to enhance and speed up the analysis of its diverse non-European health data. Through this partnership, a network of over 48,000 users in 48 different countries will potentially have access to Galatea's advanced genetic technologies. This collaboration expects to better define ancestry-based polygenic risk scores, enhance participant recruitment for clinical trials, and expand Galatea Bio’s drug discovery schemes.

Galatea Bio is a biotechnology company focused on increasing the diversity of genomic datasets by studying underrepresented populations, particularly in Latin America. It provides services such as clinical lab services aimed at improving health outcomes through genetic research. The company also provides biobanking, specifically through its flagship project, the Biobank of the Americas (BBofA), which aims to collect and store genetic data from diverse populations and leverage the data and insights gathered to develop new algorithms and pharmaceutical targets​.